Back4basebio PLC Overview
4basebio PLC

4basebio PLC Return on Equity

Valuation check: 88Q.DE's ROE is -289.02%, below the Healthcare sector average of -100.59%.

Get informed when a big investor buys or sells

+ Follow

ROE

-289.02%

Return on Equity

-289.02%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

4basebio PLC (88Q.DE) FAQ

As of the most recent data, 88Q.DE shows a ROE of -289.02%. That is below the Healthcare sector average of -100.59%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about -100.59%. 4basebio PLC is at -289.02%, which is lower that average. That is roughly 187.3% below the sector mean. Use the comparison chart on this page to see how 88Q.DE stacks up against individual peers as well.

Check the historical chart to see whether 88Q.DE's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare 4basebio PLC with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has 4basebio PLC's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -289.02%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about -100.59%, while 88Q.DE is at -289.02%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.